2',3'-dideoxycytidine 5'-triphosphate

inhibits vesicular stomatitis virus RNA synthesis

Also Known As:

2',3'-ddCTP; ddCTP-2',3'; Triphosphoric acid, P-((5-(4-amino-2-oxo-1(2H)-pyrimidinyl)tetrahydro-2-furanyl)methyl) ester, (2S-cis)-

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

1.	Murine Acquired Immunodeficiency Syndrome (MAIDS) 11/01/1993 - "In an attempt to overcome these limitations, we have tested the efficacy of the oral administration of 2',3'-dideoxycytidine (DDC) and the administration of its phosphorylated derivative, 2',3'-dideoxycytidine 5'-triphosphate (DDCTP) encapsulated into autologous red blood cells in a murine retrovirus-induced immunodeficiency model of AIDS (MAIDS). "
2.	Acquired Immunodeficiency Syndrome (AIDS) 11/01/1993 - "In an attempt to overcome these limitations, we have tested the efficacy of the oral administration of 2',3'-dideoxycytidine (DDC) and the administration of its phosphorylated derivative, 2',3'-dideoxycytidine 5'-triphosphate (DDCTP) encapsulated into autologous red blood cells in a murine retrovirus-induced immunodeficiency model of AIDS (MAIDS). "
3.	Vesicular Stomatitis 03/01/1983 - "Inhibition of vesicular stomatitis virus RNA synthesis by 2',3'-dideoxycytidine 5'-triphosphate." 03/01/1983 - "The ability of the compound 2',3'-dideoxycytidine 5'-triphosphate (ddCTP) to serve as an inhibitor of viral RNA synthesis was examined using an in vitro system that supports vesicular stomatitis virus (VSV) protein synthesis, transcription and replication. "
4.	Disease Progression 07/01/1997 - "In vivo administration of 2',3'-dideoxycytidine 5'-triphosphate (ddCTP) encapsulated into autologous erythrocytes to LP-BM5-infected mice was found to reduce infectivity and disease progression. "

1.	Oral Administration